A study to evaluate the effectiveness and safety of Apremilast in subjects with active psoriatic arthritis

Update Il y a 4 ans
Reference: EUCTR2013-001590-25

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the efficacy of apremilast 30 mg twice daily (BID) monotherapy, compared with placebo, over 24 weeks of treatment, with the primary analysis at Wk 16, in subjects with active psoriatic arthritis


Inclusion criteria

  • Psoriatic Arthritis